Recently, the British drug makers have received an approval from the US Food and Drug Administration (FDA) for its drug Brilinta (ticagrelor). It has been informed that the drug has the potential of reducing rate of thrombotic cardiovascular (CV) events in patients suffering from acute coronary syndrome (ACS).

Following the approval by the FDA, the company has launched its drug in the market. It is believed that the launch of drug would provide an opposition to physician to treat with ACS. As compared to the clopidogrel, the Brilinta is much effective in reducing heart attack and cardiovascular death if taken in combination with low-dose aspirin.

The drug is first of its kind which has shown commendable results. It has been informed that the approval of drug was supported by a study called PLATO. The PLATO study is a study of PLATelet Inhibition and Patient Outcomes.

The PLATO study has ranked Brilinta superior over clopidogrel for the prevention of another cardiovascular event in hospitalized ACS patients. However, like any other drug, Brilinta can cause side effects. The symptoms may include increase in minor bleeding. It is important to note that not all patients experience side effects of the drug.